IMDX
Insight Molecular Diagnostics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-47/100
Last price
3.38
▼ 0.29 (7.90%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
3.67
Day high
3.76
Day low
3.19
Volume
460.09K
Market cap
$110.61M
P/E (TTM)
—
52W range
2.42 – 8.51
Trailing performance
Returnvs SPY
1W
0.00%
-1.9%
1M
-18.16%
-19.3%
3M
-29.44%
-34.0%
6M
+5.30%
-12.9%
YTD
-54.93%
-69.2%
1Y
+0.90%
-15.5%
3Y
+8.33%
-73.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IMDX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
6.87M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 11, 26 | ARNO ANDREW Director |
STOCK | 32.33K | $0 | Direct |
| Jun 11, 26 | LAST ANDREW J Director |
STOCK | 26.94K | $0 | Direct |
| Jun 11, 26 | SILVERMAN LOUIS E Director |
STOCK | 26.94K | $0 | Direct |
| Apr 27, 26 | BROADWOOD PARTNERS, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 570.18K | $2.03M | Indirect |
| Apr 20, 26 | BROADWOOD PARTNERS, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 182.86K | $652.88K | Indirect |
| Mar 26, 26 | LIU JAMES YANG Officer and Treasurer |
— | 6.29K | — | Direct |
| Mar 26, 26 | RIGGS JOSHUA Chief Executive Officer |
— | 47.17K | — | Direct |
| Mar 26, 26 | JAMES ANDREA S. Chief Financial Officer |
— | 28.30K | — | Direct |
| Feb 10, 26 | BROADWOOD PARTNERS, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 521.74K | $3.87M | Indirect |
| Oct 31, 25 | JAMES ANDREA S. Chief Financial Officer |
— | 50.00K | — | Direct |
| Oct 31, 25 | JAMES ANDREA S. Chief Financial Officer |
— | 50.00K | — | Direct |
| Jul 1, 25 | ARNO ANDREW Director |
STOCK | 55.00K | $0 | Direct |
| Jul 1, 25 | LAST ANDREW J Director |
STOCK | 35.00K | $0 | Direct |
| Jul 1, 25 | SILVERMAN LOUIS E Director |
STOCK | 35.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARNO ANDREW |
Director | 184.49K | Stock Award(Grant) |
BROADWOOD PARTNERS, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
JAMES ANDREA S. |
Chief Financial Officer | 206.06K | Conversion of Exercise of derivative security |
LAST ANDREW J |
Director | 66.45K | Stock Award(Grant) |
LIU JAMES YANG |
Officer and Treasurer | 3.71K | Conversion of Exercise of derivative security |
RIGGS JOSHUA |
Chief Executive Officer | 38.37K | Conversion of Exercise of derivative security |
SILVERMAN LOUIS E |
Director | 63.51K | Stock Award(Grant) |
SMITH PATRICK W. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$110.61M
Enterprise value$95.48M
Revenue (TTM)$1.67M
Gross profit$814.00K
EBITDA$-34.54M
Net income$-49.36M
EPS (TTM)$-1.52
Free cash flow$-18.79M
Total cash$17.76M
Total debt$2.63M
Book value / share$-0.65
Shares outstanding32.72M
Float9.98M
Short % of float6.10%
Dividend yield0.00%
Beta (5Y)1.81
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.23
PEG ratio—
Price / sales—
Price / book—
EV / revenue57.17
EV / EBITDA-2.76
Gross margin48.74%
Operating margin-3815.06%
Profit margin0.00%
Return on equity—
Return on assets-57.82%
Debt / equity—
Current ratio2.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.05M | $1.88M | $1.50M | $958.00K | — | +115.6% |
| Operating revenue | $4.05M | $1.88M | $1.50M | $958.00K | — | +115.6% |
| Cost of revenue | $1.76M | $1.14M | $1.09M | $976.00K | — | +54.0% |
| Gross profit | $2.30M | $740.00K | $413.00K | -$18.00K | — | +210.5% |
| Research & development | $15.90M | $9.84M | $9.29M | $7.30M | — | +61.6% |
| Selling, general & admin | $16.11M | $13.79M | $13.29M | $21.53M | — | +16.9% |
| Total operating expense | $32.88M | $23.99M | $22.83M | $28.83M | — | +37.1% |
| Operating income | -$30.58M | -$23.25M | -$22.42M | -$28.85M | — | -31.5% |
| Net interest income | -$109.00K | -$84.00K | -$52.00K | -$83.00K | — | -29.8% |
| Pre-tax income | -$50.22M | -$60.66M | -$24.86M | -$18.61M | — | +17.2% |
| Tax provision | — | — | — | $0 | -$9.26M | — |
| Net income | -$50.22M | -$60.66M | -$27.78M | -$72.90M | — | +17.2% |
| Net income to common | -$50.22M | -$60.93M | -$28.72M | -$73.42M | — | +17.6% |
| Basic EPS | -1.65 | -4.66 | -3.75 | -20.00 | — | +64.6% |
| Diluted EPS | -1.65 | -4.66 | -3.75 | -20.00 | — | +64.6% |
| EBIT | -$50.11M | -$60.58M | -$24.80M | -$18.53M | — | +17.3% |
| EBITDA | -$47.92M | -$59.02M | -$23.12M | -$13.31M | — | +18.8% |
| Basic shares | 30.48M | 13.07M | 7.65M | 5.54M | — | +133.2% |
| Diluted shares | 30.48M | 13.07M | 7.65M | 5.54M | — | +133.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.58M | $8.64M | $9.43M | $19.99M | — | +34.1% |
| Cash & short-term investments | $11.58M | $8.64M | $9.43M | $20.43M | — | +34.1% |
| Accounts receivable | $1.13M | $1.61M | $484.00K | $2.01M | — | -30.1% |
| Inventory | $446.00K | $410.00K | $0 | — | $304.00K | +8.8% |
| Total current assets | $15.31M | $11.76M | $10.70M | $25.54M | — | +30.2% |
| Property, plant & equipment | $9.25M | $6.32M | $5.44M | $10.85M | — | +46.3% |
| Goodwill & intangibles | $0 | $14.61M | $56.59M | $61.63M | — | -100.0% |
| Total assets | $25.76M | $35.08M | $74.89M | $100.09M | — | -26.6% |
| Total current liabilities | $12.07M | $7.28M | $7.19M | $12.11M | — | +66.0% |
| Current debt | — | — | — | — | $1.31M | — |
| Total debt | $3.50M | $3.66M | $2.87M | $3.54M | — | -4.6% |
| Total liabilities | $57.22M | $47.35M | $54.42M | $65.80M | — | +20.8% |
| Retained earnings | -$400.76M | -$350.54M | -$289.88M | -$260.68M | — | -14.3% |
| Shareholder equity | -$31.46M | -$12.27M | $20.47M | $34.29M | — | -156.3% |
| Working capital | $3.23M | $4.48M | $3.50M | $13.43M | — | -27.9% |
| Net tangible assets | -$31.46M | -$26.88M | -$36.13M | -$27.34M | — | -17.0% |
| Shares issued | 28.68M | 17.45M | 8.26M | 5.93M | — | +64.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$50.22M | -$60.66M | -$27.78M | -$72.90M | +17.2% |
| Depreciation & amortisation | $2.20M | $1.56M | $1.68M | $5.22M | +40.5% |
| Stock-based compensation | $2.38M | $1.91M | $2.89M | $10.04M | +24.6% |
| Change in working capital | $2.73M | -$1.29M | -$3.97M | -$1.94M | +310.9% |
| Operating cash flow | -$22.18M | -$20.69M | -$23.32M | -$45.57M | -7.2% |
| Capital expenditure | -$3.19M | -$516.00K | -$281.00K | -$4.34M | -517.2% |
| Investing cash flow | -$3.19M | -$512.00K | -$932.00K | -$4.34M | -522.1% |
| Share buybacks | $0 | -$5.39M | -$1.12M | $0 | +100.0% |
| Financing cash flow | $28.07M | $20.43M | $12.19M | $35.81M | +37.4% |
| Free cash flow | -$25.37M | -$21.20M | -$23.61M | -$49.91M | -19.6% |
| End cash position | $12.92M | $10.34M | $11.13M | $23.20M | +25.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $239.00K | $32.00K | $1.14M | $260.00K | $518.00K | — | +646.9% |
| Operating revenue | $239.00K | $32.00K | $1.14M | $260.00K | $518.00K | — | +646.9% |
| Cost of revenue | $82.00K | $17.00K | $643.00K | $121.00K | $180.00K | — | +382.4% |
| Gross profit | $157.00K | $15.00K | $496.00K | $139.00K | $338.00K | — | +946.7% |
| Research & development | $4.49M | $4.95M | $5.83M | $3.88M | $3.27M | — | -9.4% |
| Selling, general & admin | $4.50M | $5.14M | $4.38M | $3.70M | $3.89M | — | -12.5% |
| Total operating expense | $9.24M | $10.35M | $10.45M | $7.81M | $7.38M | — | -10.6% |
| Operating income | -$9.09M | -$10.33M | -$9.95M | -$7.67M | -$7.04M | — | +12.0% |
| Net interest income | -$20.00K | -$23.00K | -$26.00K | -$29.00K | -$25.00K | — | +13.0% |
| Pre-tax income | -$11.26M | -$4.29M | -$22.95M | -$10.85M | -$9.74M | — | -162.5% |
| Tax provision | — | $0 | — | $0 | $0 | $0 | — |
| Net income | -$11.26M | -$4.29M | -$22.95M | -$10.85M | -$9.74M | — | -162.5% |
| Net income to common | -$11.26M | -$4.29M | -$22.95M | -$10.85M | -$9.74M | — | -162.5% |
| Basic EPS | -0.31 | -0.12 | -0.72 | -0.34 | -0.30 | — | -158.3% |
| Diluted EPS | -0.31 | -0.12 | -0.72 | -0.34 | -0.30 | — | -158.3% |
| EBIT | -$11.24M | -$4.27M | -$22.93M | -$10.82M | -$9.72M | — | -163.4% |
| EBITDA | -$10.57M | -$3.64M | -$22.37M | -$10.24M | -$9.16M | — | -190.8% |
| Basic shares | 36.75M | 34.52M | 32.06M | 32.03M | 32.02M | — | +6.5% |
| Diluted shares | 36.75M | 34.52M | 32.06M | 32.03M | 32.02M | — | +6.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.76M | $28.20M | $11.58M | $18.69M | $24.29M | — | -37.0% |
| Cash & short-term investments | $17.76M | $28.20M | $11.58M | $18.69M | $24.29M | — | -37.0% |
| Accounts receivable | $192.00K | $157.00K | $1.13M | $258.00K | $512.00K | — | +22.3% |
| Inventory | $207.00K | $382.00K | $446.00K | $471.00K | $693.00K | — | -45.8% |
| Total current assets | $20.54M | $30.52M | $15.31M | $21.39M | $26.84M | — | -32.7% |
| Property, plant & equipment | $8.10M | $8.91M | $9.25M | $6.49M | $6.67M | — | -9.1% |
| Goodwill & intangibles | — | — | $0 | $14.60M | $14.60M | $14.60M | — |
| Total assets | $29.44M | $40.43M | $25.76M | $43.94M | $50.52M | — | -27.2% |
| Total current liabilities | $10.29M | $12.01M | $12.07M | $7.66M | $6.65M | — | -14.3% |
| Total debt | $2.63M | $3.07M | $3.50M | $3.13M | $3.37M | — | -14.5% |
| Total liabilities | $50.74M | $51.12M | $57.22M | $53.13M | $49.42M | — | -0.7% |
| Retained earnings | -$416.31M | -$405.05M | -$400.76M | -$377.81M | -$366.95M | — | -2.8% |
| Shareholder equity | -$21.30M | -$10.69M | -$31.46M | -$9.20M | $1.10M | — | -99.2% |
| Working capital | $10.26M | $18.51M | $3.23M | $13.73M | $20.19M | — | -44.6% |
| Net tangible assets | -$21.30M | -$10.69M | -$31.46M | -$23.80M | -$13.50M | — | -99.2% |
| Shares issued | 32.62M | 32.29M | 28.68M | 28.63M | 28.62M | — | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$11.26M | -$4.29M | -$22.95M | -$10.85M | -$9.74M | -162.5% |
| Depreciation & amortisation | $665.00K | $631.00K | $563.00K | $584.00K | $559.00K | +5.4% |
| Stock-based compensation | $669.00K | $647.00K | $759.00K | $559.00K | $578.00K | +3.4% |
| Change in working capital | -$1.64M | $1.30M | $2.59M | $1.73M | -$522.00K | -226.4% |
| Operating cash flow | -$9.27M | -$7.64M | -$5.54M | -$4.63M | -$6.17M | -21.3% |
| Capital expenditure | -$779.00K | -$613.00K | -$1.48M | -$1.05M | -$349.00K | -27.1% |
| Investing cash flow | -$779.00K | -$613.00K | -$1.48M | -$1.05M | -$349.00K | -27.1% |
| Share buybacks | — | — | $0 | $0 | — | — |
| Financing cash flow | -$564.00K | $24.70M | -$252.00K | -$120.00K | -$114.00K | -102.3% |
| Free cash flow | -$10.05M | -$8.25M | -$7.02M | -$5.68M | -$6.52M | -21.8% |
| End cash position | $18.73M | $29.36M | $12.92M | $20.21M | $25.99M | -36.2% |
Options analytics
Put / call volume
1.00
Call-heavy session
Put / call open interest
1.43
Positioning, not flow
Max pain
4.00
+18.3% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
1
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
5.00
9 contracts
Heaviest put OI
4.00
15 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.23 | -0.24 | -6.2% |
| Mar 2026 | -0.26 | -0.12 | +54.3% |
| Dec 2025 | -0.24 | -0.72 | -203.2% |
| Sep 2025 | -0.24 | -0.23 | +2.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.22 | 2 | $244.28K | -6.1% |
| Next quarter | -0.23 | 2 | $473.72K | -58.4% |
| Current year | -0.93 | 2 | $960.00K | -76.3% |
| Next year | -0.80 | 2 | $6.66M | +593.8% |
Analyst targets & ownership
Mean target$8.25
High target$12.00
Low target$4.00
Implied upside144.08%
Analyst count4
ConsensusBUY
Strong buy / Buy1 / 2
Hold2
Sell / Strong sell0 / 0
Held by insiders21.00%
Held by institutions56.43%
Institutions holding47
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.59
-5.82% from price
SMA 20
3.79
-10.92% from price
SMA 50
4.16
-18.74% from price
SMA 100
4.84
-30.20% from price
SMA 200
5.06
-33.22% from price
EMA 12
3.63
-6.83% from price
EMA 26
3.84
-11.90% from price
EMA 50
4.12
-17.87% from price
RSI (14)
40.2
Neutral
MACD (12,26,9)
-0.21
Hist -0.02
ATR (14)
0.41
12.18% of price
Realised vol 30D
94.6%
Annualised
Bollinger upper
4.38
20, 2σ
Bollinger lower
3.21
20, 2σ
50 / 200 cross
Death
4.16 vs 5.06
Trend bias
Below 200
-33.22%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.64
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
94.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-69.9%
Peak to trough
Max drawdown 5Y
-97.3%
Peak to trough
ATR 14
0.41
12.18% of price
Beta (reported)
1.81
5Y monthly, from filing
Short interest
Shares short
992.47K
Prior 1.09M
Change vs prior
-8.9%
Shorts covering
% of float
6.10%
Normal
% of shares out
3.03%
Against total outstanding
Days to cover
6.2
Crowded exit
Float
9.98M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 26 | LUCID CAPITAL MARKETS | INITIATED | — | Buy |
| Aug 18, 26 | Needham | MAINTAINED | Buy | Buy |
| Feb 17, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Nov 11, 25 | Needham | MAINTAINED | Buy | Buy |
| Aug 18, 25 | Needham | MAINTAINED | Buy | Buy |
| May 21, 25 | Lake Street | MAINTAINED | Buy | Buy |
| May 13, 25 | Needham | MAINTAINED | Buy | Buy |
| Apr 8, 25 | Needham | MAINTAINED | Buy | Buy |
| Mar 28, 25 | Lake Street | INITIATED | — | Buy |
| Mar 26, 25 | Stephens & Co. | MAINTAINED | Equal-Weight | Equal-Weight |
| Mar 25, 25 | Stephens & Co. | MAINTAINED | Equal-Weight | Equal-Weight |
| Mar 25, 25 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:20
Split dateJul 25, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-21
Periodic Financial Reports
10-Q · 2026-08-10
Offering Registrations
S-8 · 2026-07-24
Corporate Changes & Voting Matters
8-K · 2026-06-17
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-30
Periodic Financial Reports
10-K · 2026-03-26
Corporate Changes & Voting Matters
8-K · 2026-02-26
Headlines
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
GlobeNewswire · 35d ago
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript
Motley Fool · 51d ago
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
MarketBeat · 51d ago
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
GlobeNewswire · 57d ago
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary
Moby · 57d ago
Oncocyte Q2 Earnings Call Highlights
MarketBeat · 57d ago
Insight Molecular Diagnostics: Q2 Earnings Snapshot
Associated Press · 58d ago
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
GlobeNewswire · 58d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.